Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

Université de Montréal

$27,000.00

Exploring the molecular signature of pheochromocytomas and paragangliomas for diagnosis, follow-up, and personalized management: paving the way for precision medicine

EF 2025-26

Résumé
Pheochromocytomas and paragangliomas (PPGLs) are rare tumours. Approximately 40% of affected people carry a mutation (a change in their genetic code), increasing the risk of PPGL. Many of these involve the Krebs cycle, the cellular mechanism of converting sugar into energy. PPGLs often secrete catecholamines, hormones that regulate the normal stress response, but become dysregulated in PPGLs, leading to potentially life-threatening complications. Moreover, PPGLs can become malignant, defined by the presence of metastasis, which significantly increases mortality. Currently, surgical resection is considered the best treatment. However, there is no clear criterion for assessing the risk of recurrence or metastasis; thus, patients must undergo regular blood tests and, in some cases, magnetic resonance imaging. Recently, researchers investigated the possibility of using Krebs cycle products (metabolites) as biomarkers for PPGL. These studies have been conducted on a limited number of patients and have examined only one metabolite, which limits their current application. My project focuses on identifying Krebs cycle metabolites as biomarkers for identifying genetic mutations and for detecting recurrence and metastasis of PPGL. It is divided into two steps: 1) Measure the association with 35 Krebs cycle metabolites and the association with mutational status in patients with PPGLs, and 2) Evaluate the association between these products and tumour size, metastasis presence and catecholamine secretion. Identifying a new biomarker could decrease the need for surgery, systemic therapy (chemotherapy and nuclear medicine therapy), and PPGL-associated complications and mortality. Moreover, patients’ follow-up could be simplified and healthcare system costs reduced.
Programme
Master's Award: Canada Graduate Research Scholarships - Master's program
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
573183
Name
Perreault Florence
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Exploring the molecular signature of pheochromocytomas and paragangliomas for diagnosis, follow-up, and personalized management: paving the way for precision medicine
Programtype2
Studentship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Adrenal Gland; Biomarkers; Endocrine Cancer
Abstract
Pheochromocytomas and paragangliomas (PPGLs) are rare tumours. Approximately 40% of affected people carry a mutation (a change in their genetic code), increasing the risk of PPGL. Many of these involve the Krebs cycle, the cellular mechanism of converting sugar into energy. PPGLs often secrete catecholamines, hormones that regulate the normal stress response, but become dysregulated in PPGLs, leading to potentially life-threatening complications. Moreover, PPGLs can become malignant, defined by the presence of metastasis, which significantly increases mortality. Currently, surgical resection is considered the best treatment. However, there is no clear criterion for assessing the risk of recurrence or metastasis; thus, patients must undergo regular blood tests and, in some cases, magnetic resonance imaging. Recently, researchers investigated the possibility of using Krebs cycle products (metabolites) as biomarkers for PPGL. These studies have been conducted on a limited number of patients and have examined only one metabolite, which limits their current application. My project focuses on identifying Krebs cycle metabolites as biomarkers for identifying genetic mutations and for detecting recurrence and metastasis of PPGL. It is divided into two steps: 1) Measure the association with 35 Krebs cycle metabolites and the association with mutational status in patients with PPGLs, and 2) Evaluate the association between these products and tumour size, metastasis presence and catecholamine secretion. Identifying a new biomarker could decrease the need for surgery, systemic therapy (chemotherapy and nuclear medicine therapy), and PPGL-associated complications and mortality. Moreover, patients’ follow-up could be simplified and healthcare system costs reduced.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Perreault, Florence
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~